BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+7.64%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.56B
AUM Growth
+$6.56B
(+0.3%)
Cap. Flow
-$210M
Cap. Flow
% of AUM
-3.2%
Top 10 Holdings %
Top 10 Hldgs %
37.22%
Holding
183
New
22
Increased
65
Reduced
79
Closed
14
Top Buys
| 1 |
DexCom
DXCM
|
$42.5M |
| 2 |
Cooper Companies
COO
|
$31.6M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$17.8M |
| 4 |
SI-BONE Inc
SIBN
|
$16.6M |
| 5 |
Steris
STE
|
$16.5M |
Top Sells
| 1 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
$114M |
| 2 |
Intuitive Surgical
ISRG
|
$59.8M |
| 3 |
Neurocrine Biosciences
NBIX
|
$51.7M |
| 4 |
Evolent Health
EVH
|
$29.3M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$28.3M |
Sector Composition
| 1 | Healthcare | 99.12% |
| 2 | Industrials | 0.77% |
| 3 | Technology | 0.02% |
| 4 | Communication Services | 0.02% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ONC
101
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $3.9M | 0.06% | 24,929 -3,671 | -13% | -$574K |
|
102
Doximity
DOCS
$12.7B
| $3.88M | 0.06% | 144,065 -119,970 | -45% | -$3.23M |
|
103
SPDR S&P 500 ETF Trust
SPY
$658B
| $3.48M | 0.05% | 6,660 +4,060 | +156% | +$2.12M |
|
104
Dr. Reddy's Laboratories
RDY
$11.8B
| $3M | 0.05% | 40,896 -20,004 | -33% | -$1.47M |
|
105
Gilead Sciences
GILD
$140B
| $2.44M | 0.04% | 33,305 -18,000 | -35% | -$1.32M |
|
|
MTEM
106
DELISTED
Molecular Templates, Inc.
MTEM
| $2.31M | 0.04% | 1,029,820 | – | – |
|
107
IQVIA
IQV
$32.4B
| $2.11M | 0.03% | 8,336 +76 | +0.9% | +$19.2K |
|
108
Teva Pharmaceuticals
TEVA
$21.1B
| $2.01M | 0.03% | +142,213 | New | +$2.01M |
|
|
NVRO
109
DELISTED
NEVRO CORP.
NVRO
| $1.95M | 0.03% | 135,235 -62,089 | -31% | -$897K |
|
110
CVS Health
CVS
$92.8B
| $1.76M | 0.03% | 22,066 -9,437 | -30% | -$753K |
|
111
Certara
CERT
$1.74B
| $1.72M | 0.03% | 95,924 +4,709 | +5% | +$84.2K |
|
112
AstraZeneca
AZN
$248B
| $1.57M | 0.02% | 23,200 -28,400 | -55% | -$1.92M |
|
113
Biogen
BIIB
$19.4B
| $1.3M | 0.02% | 6,008 -2,477 | -29% | -$534K |
|
114
Bristol-Myers Squibb
BMY
$96B
| $1.27M | 0.02% | +23,436 | New | +$1.27M |
|
115
Zoetis
ZTS
$69.3B
| $1.27M | 0.02% | 7,510 +1,720 | +30% | +$291K |
|
116
Outset Medical
OM
$247M
| $1.27M | 0.02% | 572,359 -1,187,775 | -67% | -$2.64M |
|
117
Encompass Health
EHC
$12.3B
| $1.24M | 0.02% | 14,980 +3,080 | +26% | +$254K |
|
118
Cytokinetics
CYTK
$4.23B
| $1.1M | 0.02% | 15,640 -3,260 | -17% | -$229K |
|
119
VanEck Gold Miners ETF
GDX
$19B
| $1.04M | 0.02% | 33,000 | – | – |
|
120
Johnson & Johnson
JNJ
$427B
| $1.02M | 0.02% | 6,420 -21,860 | -77% | -$3.46M |
|
121
Pfizer
PFE
$141B
| $939K | 0.01% | 33,834 +10,966 | +48% | +$304K |
|
122
Alphabet (Google) Class C
GOOG
$2.58T
| $914K | 0.01% | 6,000 | – | – |
|
123
Vaxcyte
PCVX
$4B
| $905K | 0.01% | 13,244 -2,556 | -16% | -$175K |
|
124
Krystal Biotech
KRYS
$4.27B
| $856K | 0.01% | 4,810 -3,190 | -40% | -$568K |
|
125
Alkermes
ALKS
$4.78B
| $654K | 0.01% | 24,144 -27,968 | -54% | -$757K |
|